A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants With Previously Untreated Advanced Melanoma (PRISM-MEL-301)
Study of IMC-F106C in Combination with Nivolumab in Patients with Advanced Melanoma
Sponsor: Immunocore
Enrolling: Male and Female Patients
IRB Number: AAAU9777
U.S. Govt. ID: NCT06112314
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to see if IMC-F106C, in combination with nivolumab, works better than the standard therapy (nivolumab alone or in combination with relatlimab) at making tumors stop growing or shrink. IMC-F106C has not yet been approved by the Food and Drug Administration (FDA). Nivolumab and the combination of nivolumab + relatlimab is FDA approved but not in combination with IMC-F106C.
Benjamin Izar, MD
Do You Qualify?
Are you at least 18 years old? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator